Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Cannabinoid Receptor Type 2: A Possible Target in SARS-CoV-2 (CoV-19) Infection?
Francesca Rossi, Chiara Tortora, Maura Argenziano, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 11, pp. 3809-3809
Open Access | Times Cited: 77

Showing 1-25 of 77 citing articles:

Coronavirus COV-19/SARS-CoV-2 affects women less than men: clinical response to viral infection.
Pio Conti, Alaa Younes
Journal of Biological Regulators and Homeostatic Agents/Journal of Biological Regulators & Homeostatic Agents (2020) Vol. 34, Iss. 2
Closed Access | Times Cited: 433
Cannabinoids: Therapeutic Use in Clinical Practice
Cristina Pagano, Giovanna Navarra, Laura Coppola, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 6, pp. 3344-3344
Open Access | Times Cited: 145
Botanical drugs and supplements affecting the immune response in the time of COVID‐19: Implications for research and clinical practice
Thomas Brendler, Ahmed Al‐Harrasi, Rudolf Bauer, et al.
Phytotherapy Research (2020) Vol. 35, Iss. 6, pp. 3013-3031
Closed Access | Times Cited: 96
Assessment of antiviral potencies of cannabinoids against SARS-CoV-2 using computational and in vitro approaches
Vinit Raj, Jae Gyu Park, Kiu-Hyung Cho, et al.
International Journal of Biological Macromolecules (2020) Vol. 168, pp. 474-485
Open Access | Times Cited: 95
Cannabis sativa L. as a Natural Drug Meeting the Criteria of a Multitarget Approach to Treatment
Anna Stasiłowicz-Krzemień, Anna Tomala, Irma Podolak, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 2, pp. 778-778
Open Access | Times Cited: 72
Emerging Roles of the Iron Chelators in Inflammation
Alessandra Di Paola, Chiara Tortora, Maura Argenziano, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 14, pp. 7977-7977
Open Access | Times Cited: 51
Electrochemical sensing: A prognostic tool in the fight against COVID-19
Sharda Kotru, Martin Klimuntowski, Hashim Ridha, et al.
TrAC Trends in Analytical Chemistry (2021) Vol. 136, pp. 116198-116198
Open Access | Times Cited: 50
Opportunities, Challenges and Pitfalls of Using Cannabidiol as an Adjuvant Drug in COVID-19
Barbara Malinowska, Marta Baranowska‐Kuczko, Aleksandra Kicman, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 4, pp. 1986-1986
Open Access | Times Cited: 46
Proteome-wide Mendelian randomization identifies causal links between blood proteins and severe COVID-19
Alish B. Palmos, Vincent Millischer, David Menon, et al.
PLoS Genetics (2022) Vol. 18, Iss. 3, pp. e1010042-e1010042
Open Access | Times Cited: 29
Cannabigerol and Cannabicyclol Block SARS-CoV-2 Cell Fusion
Nica Classen, Thanet Pitakbut, Michael Schöfbänker, et al.
Planta Medica (2024) Vol. 90, Iss. 09, pp. 717-725
Closed Access | Times Cited: 6
Repurposing existing drugs for COVID-19: an endocrinology perspective
Flavio Cadegiani
BMC Endocrine Disorders (2020) Vol. 20, Iss. 1
Open Access | Times Cited: 45
Anti-Inflammatory and Antiviral Effects of Cannabinoids in Inhibiting and Preventing SARS-CoV-2 Infection
Marcin Janecki, Michał Graczyk, Agata Anna Lewandowska, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 8, pp. 4170-4170
Open Access | Times Cited: 27
Cannabis for COVID-19: Can Cannabinoids Quell the Cytokine Storm?
Emmanuel S. Onaivi, Venkatanarayanan Sharma
Future Science OA (2020) Vol. 6, Iss. 8
Open Access | Times Cited: 37
Potential Therapeutic Agents and Associated Bioassay Data for COVID-19 and Related Human Coronavirus Infections
Qiongqiong Angela Zhou, Junko Kato-Weinstein, Yingzhu Li, et al.
ACS Pharmacology & Translational Science (2020) Vol. 3, Iss. 5, pp. 813-834
Open Access | Times Cited: 36
Cannabinoids in Medicine: Cancer, Immunity, and Microbial Diseases
Paweł Śledziński, Agnieszka Nowak, Joanna Zeyland
International Journal of Molecular Sciences (2020) Vol. 22, Iss. 1, pp. 263-263
Open Access | Times Cited: 34
Tocilizumab-coated solid lipid nanoparticles loaded with cannabidiol as a novel drug delivery strategy for treating COVID-19: A review
Aleksandra Zielińska, Piotr Eder, Jacek Karczewski, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 11
Mechanism deconvolution of Qing Fei Pai Du decoction for treatment of Coronavirus Disease 2019 (COVID-19) by label-free integrative pharmacology assays
Fangfang Xu, Tao Hou, Aijin Shen, et al.
Journal of Ethnopharmacology (2021) Vol. 280, pp. 114488-114488
Open Access | Times Cited: 25
The potential of cannabinoids and inhibitors of endocannabinoid degradation in respiratory diseases
Aleksandra Kicman, Anna Pędzińska‐Betiuk, Hanna Kozłowska
European Journal of Pharmacology (2021) Vol. 911, pp. 174560-174560
Open Access | Times Cited: 25
Antimicrobial and Antiviral (SARS-CoV-2) Potential of Cannabinoids and Cannabis sativa: A Comprehensive Review
Md Sultan Mahmud, Mohammad Sorowar Hossain, A T M Faiz Ahmed, et al.
Molecules (2021) Vol. 26, Iss. 23, pp. 7216-7216
Open Access | Times Cited: 25
In quest of a new therapeutic approach in COVID-19: the endocannabinoid system
Ondine Lucaciu, Ovidiu Aghiorghiesei, Nausica Bianca Petrescu, et al.
Drug Metabolism Reviews (2021) Vol. 53, Iss. 4, pp. 478-490
Open Access | Times Cited: 24
The Therapeutic Potential of Cannabis in Counteracting Oxidative Stress and Inflammation
Michał Graczyk, Agata Anna Lewandowska, Tomasz Dzierżanowski
Molecules (2021) Vol. 26, Iss. 15, pp. 4551-4551
Open Access | Times Cited: 24
Therapeutic Effects of Cannabinoids and Their Applications in COVID-19 Treatment
Rebeca Pérez, Talita Glaser, Cecilia Villegas, et al.
Life (2022) Vol. 12, Iss. 12, pp. 2117-2117
Open Access | Times Cited: 16
Cannabidiol and Terpene Formulation Reducing SARS-CoV-2 Infectivity Tackling a Therapeutic Strategy
Susana Santos, Pedro Barata, M.A.J. Charmier, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 14
Dual inhibition of CB1 receptors and iNOS, as a potential novel approach to the pharmacological management of acute and long COVID‐19
Reşat Çınar, Malliga R. Iyer, George Kunos
British Journal of Pharmacology (2021) Vol. 179, Iss. 10, pp. 2121-2127
Open Access | Times Cited: 19
SARS-CoV-2: Current trends in emerging variants, pathogenesis, immune responses, potential therapeutic, and vaccine development strategies
Ali Salimi Jeda, Sina Abbassi, Atieh Mousavizadeh, et al.
International Immunopharmacology (2021) Vol. 101, pp. 108232-108232
Open Access | Times Cited: 18
Page 1 - Next Page

Scroll to top